Daniele Sblattero Selected Research

Transglutaminases

1/2017	Transglutaminase 2-specific coeliac disease autoantibodies induce morphological changes and signs of inflammation in the small-bowel mucosa of mice.
1/2017	Celiac anti-type 2 transglutaminase antibodies induce differential effects in fibroblasts from celiac disease patients and from healthy subjects.
1/2014	Structural basis for the recognition in an idiotype-anti-idiotype antibody complex related to celiac disease.
3/2010	Anti transglutaminase antibodies cause ataxia in mice.
2/2009	Mucosal tissue transglutaminase expression in celiac disease.
8/2007	Construction of miniantibodies for the in vivo study of human autoimmune diseases in animal models.
6/2007	Gluten ataxia: passive transfer in a mouse model.
4/2007	Humoral immune response to tissue transglutaminase is related to epithelial cell proliferation in celiac disease.
1/2004	Testing for anti-human transglutaminase antibodies in saliva is not useful for diagnosis of celiac disease.
11/2002	The analysis of the fine specificity of celiac disease antibodies using tissue transglutaminase fragments.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniele Sblattero Research Topics

Disease

22	Celiac Disease (Celiac Sprue) 01/2019 - 11/2002
7	Neoplasms (Cancer) 01/2019 - 07/2005
6	Inflammation (Inflammations) 08/2021 - 08/2012
5	Rheumatoid Arthritis 01/2021 - 01/2012
5	Autoimmune Diseases (Autoimmune Disease) 01/2014 - 06/2007
4	Arthritis (Polyarthritis) 01/2019 - 10/2002
3	Infections 01/2020 - 01/2012
3	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 07/2009 - 05/2005
2	Disease Progression 01/2020 - 01/2017
2	Thrombosis (Thrombus) 05/2014 - 10/2005
2	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 05/2014 - 10/2005
2	Neoplasm Metastasis (Metastasis) 05/2014 - 10/2010
2	Ataxia (Dyssynergia) 03/2010 - 06/2007
1	Marginal Zone B-Cell Lymphoma (MALT Lymphoma) 08/2021
1	Cystic Fibrosis (Mucoviscidosis) 11/2020
1	Ovarian Neoplasms (Ovarian Cancer) 01/2019
1	Ascites 01/2019
1	Fibrosis (Cirrhosis) 01/2019
1	Experimental Arthritis 01/2019
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2017
1	Multiple Sclerosis 01/2017
1	Reperfusion Injury 01/2017
1	Intestinal Diseases (Diseases, Intestinal) 01/2017
1	Malignant Mesothelioma 01/2017
1	Hypoxia (Hypoxemia) 01/2017
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2017
1	Melioidosis 11/2015
1	Parkinson Disease (Parkinson's Disease) 01/2015
1	Chronic Disease (Chronic Diseases) 01/2013
1	Systemic Scleroderma (Systemic Sclerosis) 01/2012
1	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 03/2010
1	Neurologic Manifestations (Neurological Manifestations) 06/2007
1	Malabsorption Syndromes (Malabsorption Syndrome) 06/2007
1	Dermatitis Herpetiformis (Disease, Duhring's) 06/2007
1	Thyroiditis 06/2007
1	Atrophy 06/2007
1	IgA Deficiency 07/2006
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 07/2005
1	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 08/2003
1	Cardiomyopathies (Cardiomyopathy) 08/2003

Drug/Important Bio-Agent (IBA)

21	AntibodiesIBA 01/2017 - 11/2002
17	Protein Glutamine gamma Glutamyltransferase 2IBA 01/2019 - 11/2002
12	AutoantibodiesIBA 01/2019 - 04/2007
10	TransglutaminasesIBA 01/2017 - 11/2002
9	Proteins (Proteins, Gene)FDA Link 08/2021 - 11/2002
8	AntigensIBA 01/2020 - 10/2002
7	AutoantigensIBA 01/2014 - 11/2002
6	Glutens (Glutelin)IBA 01/2019 - 02/2004
5	Complement System Proteins (Complement)IBA 01/2017 - 07/2005
5	GliadinIBA 01/2013 - 11/2002
4	Immunoglobulin A (IgA)IBA 09/2010 - 08/2003
3	Biological ProductsIBA 01/2021 - 05/2014
3	Immunoglobulin G (IgG)IBA 01/2021 - 08/2003
2	Adalimumab (Humira)FDA Link 01/2021 - 10/2015
2	EpitopesIBA 01/2020 - 02/2004
2	EnzymesIBA 01/2019 - 04/2007
2	Peptides (Polypeptides)IBA 01/2017 - 08/2012
2	OsteopontinIBA 01/2017 - 01/2012
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2015 - 08/2012
2	Pharmaceutical PreparationsIBA 05/2014 - 10/2010
2	Neutralizing AntibodiesIBA 01/2013 - 08/2012
2	Monoclonal AntibodiesIBA 02/2009 - 07/2005
1	Therapeutic UsesIBA 01/2021
1	Fibronectins (Fibronectin)IBA 01/2019
1	PlatinumIBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 01/2019
1	Immunoglobulins (Immunoglobulin)IBA 01/2019
1	cyclic arginine-glycine-aspartic acid peptideIBA 01/2017
1	AsbestosIBA 01/2017
1	Type V Secretion SystemsIBA 11/2015
1	VaccinesIBA 11/2015
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 10/2015
1	Infliximab (Remicade)FDA Link 10/2015
1	ProdrugsIBA 10/2015
1	Ubiquitin Thiolesterase (Ubiquitin Carboxy-Terminal Hydrolase)IBA 01/2015
1	UbiquitinIBA 01/2015
1	EsterasesIBA 01/2015
1	Long Noncoding RNAIBA 01/2015
1	Glycoproteins (Glycoprotein)IBA 05/2014
1	LigandsIBA 05/2014
1	Anti-Idiotypic AntibodiesIBA 01/2014
1	Interleukin-6 (Interleukin 6)IBA 08/2012
1	Recombinant ProteinsIBA 08/2012
1	CollagenIBA 08/2012
1	Small Interfering RNA (siRNA)IBA 07/2012
1	Interleukin-17 (Interleukin 17)IBA 01/2012
1	CytokinesIBA 01/2012
1	Single-Chain AntibodiesIBA 03/2010
1	A-factor (Streptomyces)IBA 03/2008
1	Iodide Peroxidase (Deiodinase)IBA 06/2007
1	PhalloidineIBA 04/2007
1	RhodaminesIBA 04/2007
1	beta 2-Glycoprotein I (Apolipoprotein H)IBA 10/2005
1	Rituximab (Mabthera)FDA Link 07/2005
1	Insulin (Novolin)FDA Link 05/2005

Therapy/Procedure

5	Therapeutics 01/2021 - 01/2012
2	Gluten-Free Diet 07/2013 - 07/2006
1	Drug Therapy (Chemotherapy) 01/2019
1	Intraventricular Injections 03/2010